Stocks
Definium Therapeutics, Inc.DFTX
NASDAQHealthcareBiotechnology$35.67
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted therapies for rare and serious diseases, with a focus on genetic disorders. Its pipeline includes investigational drugs in early-to-mid stage trials, and investors track it for potential catalysts from upcoming clinical data readouts.
52W Range: $10.46-$49.70
Congressional Interest in Definium Therapeutics, Inc. (DFTX)
No congressional trades have been disclosed for Definium Therapeutics, Inc. (DFTX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading DFTX?
No congressional trades found for this stock.